Repare Therapeutics Inc (RPTX)

Nov 13, 2024

Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher - Simply Wall St

Nov 13, 2024

Nov 13, 2024

Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Yahoo Finance

Nov 13, 2024

Nov 13, 2024

Repare Therapeutics partners with NCI on cancer drug By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 12, 2024

Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News

Nov 12, 2024

Nov 12, 2024

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace

Nov 12, 2024

Nov 12, 2024

Repare Therapeutics partners with NCI on cancer drug - Investing.com India

Nov 12, 2024

Nov 12, 2024

Repare Therapeutics Partners with NCI to Advance Breakthrough Cancer Drug Camonsertib | RPTX Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 08, 2024

Nov 08, 2024

Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks

Nov 08, 2024

Nov 07, 2024

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - CRISPR Medicine News

Nov 07, 2024

Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024

Oct 24, 2024

Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 24, 2024

Oct 24, 2024

Repare Therapeutics’ individualised anaemia management trial shows promise - Yahoo Finance

Oct 24, 2024

Oct 23, 2024

Press Release Service: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News

Oct 23, 2024

Oct 23, 2024

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - BioSpace

Oct 23, 2024

Oct 23, 2024

Repare Therapeutics reports progress in cancer trial - Investing.com India

Oct 23, 2024

Oct 19, 2024

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug - MSN

Oct 19, 2024

Oct 16, 2024

Dimensional Fund Advisors LP Sells 27,504 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

Oct 16, 2024

Oct 14, 2024

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - CRISPR Medicine News

Oct 14, 2024

Oct 14, 2024

Repare Therapeutics doses first subject in Phase I solid tumour trial - Yahoo! Voices

Oct 14, 2024

Oct 14, 2024

Repare Therapeutics begins trial for novel cancer drug By Investing.com - Investing.com Australia

Oct 14, 2024

Oct 12, 2024

Marshall Wace LLP Takes Position in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

Oct 12, 2024

Oct 11, 2024

Repare Therapeutics Inc. Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor - Marketscreener.com

Oct 11, 2024

Oct 05, 2024

There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise - Simply Wall St

Oct 05, 2024

Oct 02, 2024

XTX Topco Ltd Makes New Investment in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

Oct 02, 2024

Oct 01, 2024

Repare Therapeutics reports promising trial results for cancer drug - Investing.com India

Oct 01, 2024

Oct 01, 2024

Investing in Repare Therapeutics Inc (RPTX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Oct 01, 2024

Oct 01, 2024

Repare Therapeutics Inc (RPTX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Oct 01, 2024

Oct 01, 2024

Press Release Service: Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - CRISPR Medicine News

Oct 01, 2024

Sep 30, 2024

Repare Therapeutics reports promising trial results for cancer drug By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 30, 2024

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - BioSpace

Sep 30, 2024

Sep 30, 2024

Stocks to Watch: CVS Health, PepsiCo, Repare Therapeutics - MarketWatch

Sep 30, 2024

Sep 30, 2024

Repare Therapeutics Gets Encouraging Early Phase 1 Data for Camonsertib - MarketWatch

Sep 30, 2024

Sep 28, 2024

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Blue Owl Capital Holdings LP - MarketBeat

Sep 28, 2024

Sep 27, 2024

Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company - Yahoo Finance

Sep 27, 2024

Sep 25, 2024

Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat

Sep 25, 2024

Sep 25, 2024

Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex

Sep 25, 2024

Sep 25, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Public Employees Retirement Association of Colorado - Defense World

Sep 25, 2024

Sep 25, 2024

DNA Repair Drugs Market Freshly Published Findings Size, Key Manufacturers, Demand Analysis, Share And Over... - WhaTech

Sep 25, 2024